{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:43:50Z","timestamp":1761853430409,"version":"build-2065373602"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"DOI":"10.7759\/cureus.95767","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:40:52Z","timestamp":1761853252000},"source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Use of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Lower Readmission Rates After Coronary Artery Bypass Grafting (CABG) in Adults With Congenital Heart Disease"],"prefix":"10.7759","author":[{"given":"Jason H","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joey","family":"McKinnerney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taysir","family":"Al Janabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael  N","family":"Vranian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.025","article-title":"Characteristics of adults with congenital heart defects in the United States","volume":"76","author":"Gurvitz M","year":"2020","unstructured":"Gurvitz M, Dunn JE, Bhatt A, et al.. Characteristics of adults with congenital heart defects in the United States. J Am Coll Cardiol. 2020, 76:175-82. 10.1016\/j.jacc.2020.05.025","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2017-204326","article-title":"Update on congenital heart disease and sudden infant\/perinatal death: from history to future trends","volume":"70","author":"Ottaviani G","year":"2017","unstructured":"Ottaviani G, Buja LM. Update on congenital heart disease and sudden infant\/perinatal death: from history to future trends. J Clin Pathol. 2017, 70:555-62. 10.1136\/jclinpath-2017-204326","journal-title":"J Clin Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.003076","article-title":"Congenital heart disease with and without cyanotic potential and the long-term risk of diabetes mellitus: a population-based follow-up study","volume":"5","author":"Madsen NL","year":"2016","unstructured":"Madsen NL, Marino BS, Woo JG, Thomsen RW, Videb\u0153k J, Laursen HB, Olsen M. Congenital heart disease with and without cyanotic potential and the long-term risk of diabetes mellitus: a population-based follow-up study. J Am Heart Assoc. 2016, 5:10.1161\/JAHA.115.003076","journal-title":"J Am Heart Assoc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17519","article-title":"Protective effects of metformin in various cardiovascular diseases: clinical evidence and AMPK-dependent mechanisms","volume":"26","author":"Bu Y","year":"2022","unstructured":"Bu Y, Peng M, Tang X, Xu X, Wu Y, Chen AF, Yang X. Protective effects of metformin in various cardiovascular diseases: clinical evidence and AMPK-dependent mechanisms. J Cell Mol Med. 2022, 26:4886-903. 10.1111\/jcmm.17519","journal-title":"J Cell Mol Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085799","article-title":"GLP-1 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang JY","year":"2023","unstructured":"Wang JY, Wang QW, Yang XY, et al.. GLP-1 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol (Lausanne). 2023, 14:1085799. 10.3389\/fendo.2023.1085799","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano D","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, et al.. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021, 20:189. 10.1186\/s12933-021-01366-8","journal-title":"Cardiovasc Diabetol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2018.09.014","article-title":"Coronary artery bypass graft surgery complications: a review for emergency clinicians","volume":"36","author":"Montrief T","year":"2018","unstructured":"Montrief T, Koyfman A, Long B. Coronary artery bypass graft surgery complications: a review for emergency clinicians. Am J Emerg Med. 2018, 36:2289-97. 10.1016\/j.ajem.2018.09.014","journal-title":"Am J Emerg Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2022.100026","article-title":"Atherosclerotic cardiovascular disease in adults with congenital heart disease","volume":"1","author":"Egbe AC","year":"2022","unstructured":"Egbe AC, Miranda WR, Lopez-Jimenez F, Connolly HM. Atherosclerotic cardiovascular disease in adults with congenital heart disease. JACC Adv. 2022, 1:100026. 10.1016\/j.jacadv.2022.100026","journal-title":"JACC Adv"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006614","article-title":"Association of perioperative glucagon-like peptide-1 receptor agonist use and postoperative outcomes","volume":"281","author":"Aschen SZ","year":"2025","unstructured":"Aschen SZ, Zhang A, O'Connell GM, Salingaros S, Andy C, Rohde CH, Spector JA. Association of perioperative glucagon-like peptide-1 receptor agonist use and postoperative outcomes. Ann Surg. 2025, 281:600-7. 10.1097\/SLA.0000000000006614","journal-title":"Ann Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2024.05.079","article-title":"Decreased risk of readmission and complications with preoperative GLP-1 analog use in patients undergoing primary total joint arthroplasty","volume":"39","author":"Buddhiraju A","year":"2024","unstructured":"Buddhiraju A, Kagabo W, Khanuja HS, Oni JK, Nikkel LE, Hegde V. Decreased risk of readmission and complications with preoperative GLP-1 analog use in patients undergoing primary total joint arthroplasty. J Arthroplasty. 2024, 39:2911-2915.e1. 10.1016\/j.arth.2024.05.079","journal-title":"J Arthroplasty"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-022-01989-1","article-title":"Morbidity and mortality in adults with congenital heart defects in the third and fourth life decade","volume":"111","author":"M\u00fcller MJ","year":"2022","unstructured":"M\u00fcller MJ, Norozi K, Caroline J, et al.. Morbidity and mortality in adults with congenital heart defects in the third and fourth life decade. Clin Res Cardiol. 2022, 111:900-11. 10.1007\/s00392-022-01989-1","journal-title":"Clin Res Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2024.11.025","article-title":"Perioperative use of GLP-1 receptor agonists in patients undergoing cardiac procedures: a scoping review","volume":"34","author":"Wookey O","year":"2025","unstructured":"Wookey O, Galligan A, Wilkie B, MacIsaac A, Paratz E. Perioperative use of GLP-1 receptor agonists in patients undergoing cardiac procedures: a scoping review. Heart Lung Circ. 2025, 34:105-17. 10.1016\/j.hlc.2024.11.025","journal-title":"Heart Lung Circ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/endocrines5030023","article-title":"Glucagon-like peptide-1 receptor agonists: are they as good as they seem? A systematic review of severe adverse effects","volume":"5","author":"Sharma P","year":"2024","unstructured":"Sharma P, Buddhavarapu V, Dhillon G, et al.. Glucagon-like peptide-1 receptor agonists: are they as good as they seem? A systematic review of severe adverse effects. Endocrines. 2024, 5:323-33. 10.3390\/endocrines5030023","journal-title":"Endocrines"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2022-0093","article-title":"Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: a systematic review and meta-analysis of randomized control trials","volume":"19","author":"Watkins AR","year":"2023","unstructured":"Watkins AR, Fialka N, El-Andari R, Kang JJ, Bozso SJ, Nagendran J. Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: a systematic review and meta-analysis of randomized control trials. Future Cardiol. 2023, 19:105-15. 10.2217\/fca-2022-0093","journal-title":"Future Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15636","article-title":"Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists","volume":"26","author":"Klonoff DC","year":"2024","unstructured":"Klonoff DC, Kim SH, Galindo RJ, et al.. Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2024, 26:3128-36. 10.1111\/dom.15636","journal-title":"Diabetes Obes Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02548-w","article-title":"Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study","volume":"24","author":"Madsen JM","year":"2025","unstructured":"Madsen JM, Kjaer AK, L\u00f8nborg JT, K\u00f8ber L, Glinge C, Jabbari R, Engstr\u00f8m T. Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2025, 24:4. 10.1186\/s12933-024-02548-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1366572","article-title":"Challenges and opportunities in patients with adult congenital heart disease, a narrative review","volume":"11","author":"Fabbri M","year":"2024","unstructured":"Fabbri M, Sahu A. Challenges and opportunities in patients with adult congenital heart disease, a narrative review. Front Cardiovasc Med. 2024, 11:1366572. 10.3389\/fcvm.2024.1366572","journal-title":"Front Cardiovasc Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-025-02710-8","article-title":"Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis","author":"Gonzales-Uribe A","year":"2025","unstructured":"Gonzales-Uribe A, Ruiz-Cortez R, Collantes-Silva N, et al.. Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis. Clin Res Cardiol. 2025, 10.1007\/s00392-025-02710-8","journal-title":"Clin Res Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1959","article-title":"Perioperative tight glucose control reduces postoperative adverse events in nondiabetic cardiac surgery patients","volume":"100","author":"Bl\u00e1ha J","year":"2015","unstructured":"Bl\u00e1ha J, Mr\u00e1z M, Kopeck\u00fd P, et al.. Perioperative tight glucose control reduces postoperative adverse events in nondiabetic cardiac surgery patients. J Clin Endocrinol Metab. 2015, 100:3081-9. 10.1210\/jc.2015-1959","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi SF","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, et al.. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023, 14:1148209. 10.3389\/fimmu.2023.1148209","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02607-w","article-title":"The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)","volume":"24","author":"Hullon D","year":"2025","unstructured":"Hullon D, Subeh GK, Volkova Y, Janiec K, Trach A, Mnevets R. The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF). Cardiovasc Diabetol. 2025, 24:70. 10.1186\/s12933-025-02607-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.01.062","article-title":"Emerging research directions in adult congenital heart disease: a report from an NHLBI\/ACHA Working Group","volume":"67","author":"Gurvitz M","year":"2016","unstructured":"Gurvitz M, Burns KM, Brindis R, et al.. Emerging research directions in adult congenital heart disease: a report from an NHLBI\/ACHA Working Group. J Am Coll Cardiol. 2016, 67:1956-64. 10.1016\/j.jacc.2016.01.062","journal-title":"J Am Coll Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/425959-perioperative-use-of-glucagon-like-peptide-1-glp-1-receptor-agonists-lower-readmission-rates-after-coronary-artery-bypass-grafting-cabg-in-adults-with-congenital-heart-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:40:52Z","timestamp":1761853252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/425959-perioperative-use-of-glucagon-like-peptide-1-glp-1-receptor-agonists-lower-readmission-rates-after-coronary-artery-bypass-grafting-cabg-in-adults-with-congenital-heart-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.95767","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}